



Evidence That Tumor Microenvironment Initiates Epithelial-To-Mesenchymal Transition and Calebin A can Suppress it in Colorectal Cancer Cells

Constanze Buhrmann^{1,2}, Aranka Brockmueller¹, Choudhary Harsha³, Ajaikumar B. Kunnumakkara³, Peter Kubatka⁴, Bharat B. Aggarwal⁵ and Mehdi Shakibaei¹*

¹Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Faculty of Medicine, Institute of Anatomy, Ludwig-Maximilian-University Munich, Munich, Germany, ²Faculty of Medicine, Institute of Anatomy and Cell Biology, University of Augsburg, Augsburg, Germany, ³Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India, ⁴Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia, ⁵Inflammation Research Center, San Diego, CA, United States

OPEN ACCESS

Edited by: Cristiana Perrotta, University of Milan, Italy

Reviewed by:

Héctor R. Contreras, University of Chile, Chile Dingcheng Gao, Cornell University, United States

*Correspondence:

Mehdi Shakibaei mehdi.shakibaei@med.unimuenchen.de

Specialty section:

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

> **Received:** 14 May 2021 **Accepted:** 23 June 2021 **Published:** 02 July 2021

Citation:

Buhrmann C, Brockmueller A, Harsha C, Kunnumakkara AB, Kubatka P, Aggarwal BB and Shakibaei M (2021) Evidence That Tumor Microenvironment Initiates Epithelial-To-Mesenchymal Transition and Calebin A can Suppress it in Colorectal Cancer Cells. Front. Pharmacol. 12:699842. doi: 10.3389/fphar.2021.699842 **Background:** Tumor microenvironment (TME) has a pivotal impact on tumor progression, and epithelial-mesenchymal transition (EMT) is an extremely crucial initial event in the metastatic process in colorectal cancer (CRC) that is not yet fully understood. Calebin A (an ingredient in *Curcuma longa*) has been shown to repress CRC tumor growth. However, whether Calebin A is able to abrogate TME-induced EMT in CRC was investigated based on the underlying pathways.

Methods: CRC cell lines (HCT116, RKO) were exposed with Calebin A and/or a FAK inhibitor, cytochalasin D (CD) to investigate the action of Calebin A in TME-induced EMT-related tumor progression.

Results: TME induced viability, proliferation, and increased invasiveness in 3D-alginate CRC cultures. In addition, TME stimulated stabilization of the master EMT-related transcription factor (Slug), which was accompanied by changes in the expression patterns of EMT-associated biomarkers. Moreover, TME resulted in stimulation of NF- κ B, TGF- β 1, and FAK signaling pathways. However, these effects were dramatically reduced by Calebin A, comparable to FAK inhibitor or CD. Finally, TME induced a functional association between NF- κ B and Slug, suggesting that a synergistic interaction between the two transcription factors is required for initiation of EMT and tumor cell invasion, whereas Calebin A strongly inhibited this binding and subsequent CRC cell migration.

Conclusion: We propose for the first time that Calebin A modulates TME-induced EMT in CRC cells, at least partially through the NF- κ B/Slug axis, TGF- β 1, and FAK signaling. Thus, Calebin A appears to be a potential agent for the prevention and management of CRC.

Keywords: tumor microenvironment, colorecal cancer, Calebin A, EMT, focal adhesion kinase, NF- kappa B, slug, TGF - β 1

1

INTRODUCTION

Colorectal cancer (CRC) is ranked third in incidence and second in associated mortality worldwide (Bray et al., 2018; Bray et al., 2020; Siegel et al., 2020). CRC rising incidences have been linked to the aging population, poor lifestyle, and diet in particular, among other factors (Dekker et al., 2019). Although, it has been observed that the incidence of CRC has been decreasing in recent years (Mauri et al., 2019), additionally it has been reported that the quality of life is often compromised by chronic side effects in CRC patients after therapies (Buccafusca et al., 2019). This indicates the importance of developing an alternative effective treatment option with few side effects in order to control the overall CRC mortality statistics.

The major etiological factor of CRC is chronic infection in the gastrointestinal tract that causes an active pro-inflammatory tumor microenvironment (TME) supported by defensive cells such as T-lymphocytes, macrophages, natural killer cells and other cells that may play a key role in tumor development (Elinav et al., 2013). The TME contributes significantly to the proliferation, survival, and migration of the underlying cellular neoplastic system. In addition, tumor cells possess some of the signaling proteins of the inherent immune system, such as chemokines, cytokines and their receptors that contribute to migration and metastasis (Coussens and Werb, 2002). Further, the inflammatory TME attracts immune cells and other protective cells which secrete pro-inflammatory mediators. These factors, in turn, can lead to greater alteration of intracellular signaling pathways, initiation and accumulation of mutations in tumor cells that induce active and rapid proliferation and protect the cancer cells from apoptosis. As a result, CRC cells lose the epithelial phenotype and simultaneously acquire the mesenchymal phenotype, thus undergoing an epithelial-mesenchymal transition (EMT) that gives them the ability to metastasize (Virchow, 1881; Coussens and Werb, 2002; de Visser et al., 2006; Medzhitov, 2008; Buhrmann et al., 2020a). Therefore, targeting the TME might provide new therapeutic approaches for controlling tumor development.

EMT and its associated progression and occurrence of metastasis is a major contributor to mortality in CRC patients, and the underlying mechanisms are still under exploration. EMT has been shown to play a determinant function in cancer development as it leads to disruption of cell-cell adherences, extracellular matrix (ECM) re-modelling and increased motility of the tumor cells (Martin, 2014). In addition, EMT inhibits E-cadherin expression, causing impaired adhesion and cell polarity during the development of epithelial tumors (carcinomas) and becomes evident at the stage of invasion (mesenchymal phenomenon), when tumor cells detach from the primary tumor and acquire the ability to cross the surrounding area (Behrens et al., 1992; Stetler-Stevenson et al., 1993; Christofori and Semb, 1999; Tepass et al., 2000; Thiery, 2002; Prieto-García et al., 2017) and this promotes formation of cancer stem cells (Mani et al., 2008; Polyak and Weinberg, 2009). Interestingly, it has been previously reported that downregulation of E-cadherin expression in tumor cells may involve both genetic and epigenetic modifications (Christofori and Semb,

1999). Among the epigenetic and genetic modifications, excessive methylation of the E-cadherin promoter and transcriptional suppression are observed as major activities in most carcinomas (Yoshiura et al., 1995; Tamura et al., 2000; Cheng et al., 2001; Hajra et al., 2002). In addition, transcriptional repressors of the Snail zinc finger transcription factor family, such as Snail and Slug, play an essential role in the activation and induction of EMT, as this alters the expression patterns of EMT biomarkers in favor of the mesenchymal phenotype (LaBonne and Bronner-Fraser, 2000; del Barrio and Nieto, 2002; Nieto, 2002). Indeed, the inflammatory TME has been further shown to induce cancer initiation, and metastasis through stimulating the EMT process (Buhrmann et al., 2016). Stromal cells in the TME are recognized to have a pivotal function in the stimulation of EMT in tumor cells (Guo and Deng, 2018) and TME-mediated EMT induction in tumor cells is stimulated by activating various cell signaling pathways including TNF-B, NF-KB and Wnt signaling connected with cancer progression (Jing et al., 2011). Moreover, pro-inflammatory TNF-a or TNF-b, have been previously reported to act as potential endogenous tumorpromoting factors and an important mechanism of cytokines in this action is to induce EMT in different types of tumor cells (Soria et al., 2011; Buhrmann et al., 2020a). In addition, focal adhesion kinase (FAK), cytoskeletal proteins and their receptors have previously demonstrated to have a major function in the context of EMT-mediated tumor cell survival and invasion, as well as progression. These upstream signaling molecules are potential therapeutic targets to control tumor metastasis as well as tumor proliferation (Seguin et al., 2015).

NF-κB is a very important and pro-inflammatory transcription factor that is induced by diverse inflammatory signals, oxidative stress, and various carcinogens in diverse cells. Moreover, NF-κB is known to initially reside in an inactive state in the cytoplasm in various cells and consists of a heterotrimer with p50 and p65 subunits and an inhibitory IκBα subunit (Bhat-Nakshatri et al., 2010). It has been shown that most of the processes involved in pro-inflammatory and carcinogenic pathways are linked to NF-κB signaling. After activation and phosphorylation, NF-κB translocates to the nucleus to control the protein expression of pro-inflammatory genes. Interestingly, it is found that phosphorylation of NF-κB leads to various stages of inflammation, survival, proliferation, migration, angiogenesis, tumor development, and also tumor cell metastasis and drug resistance (Aggarwal, 2004).

The transforming growth factor- β 1 (TGF- β 1) is identified to be a potent enabler of EMT in the initial phase of tumor progression and tumor metastasis (Buhrmann et al., 2016). In addition, TGF- β 1 specifically promotes receptor complex activity, leading to the initiation of Smad2 phosphorylation in the nucleus, in which they functionally associate to transcription factors such as Snail and Slug, suppressing the expression of epithelial biomarkers and stimulating the expression of mesenchymal biomarkers at mRNA level (Zhang et al., 2018).

Further, activation of EMT signaling pathways has been described to be regulated at the epigenetic and post-translational level (Prieto-García et al., 2017) and identification of novel agents targeting EMT may provide possible new

therapeutic approaches in cancer treatment (Kalluri and Weinberg, 2009). Calebin A [4-(3-methoxy-4-hydroxyphenyl)-2-oxo-3-enebutanyl 3-(3-methoxy-4-hydroxyphenyl) propenoate] is drived from curcumin-free turmeric (*Curcuma longa L., Zingiberaceae*), first described by Park and Kim (Park and Kim, 2002) and since then, other isomers of Calebin A have been discovered (Zeng et al., 2007). Calebin A has been reported to possess potent anti-inflammatory and anti-tumor potential, such as inhibiting cell viability, proliferation, and migration, and promoting apoptosis in various resistant and solid tumor cells by blocking several cellular signaling pathways (Aggarwal et al., 2013; Buhrmann et al., 2019; Nair et al., 2019; Buhrmann et al., 2020a).

However, so far, to our knowledge, there are not any clear studies published on the possible inhibition of EMT process and metastasis in CRC-TME by Calebin A. Therefore, the present study targeted to test the sub-regulatory promotions of Calebin A on CRC cells in a pro-inflammatory multicellular TME model. In this work, we report for the first time that Calebin A suppresses TME-induced invasion and malignancy of CRC cells by modulating EMT signaling pathways, thus highlighting Calebin A.

MATERIALS AND METHODS

Antibodies and Chemicals

Monoclonal antibodies to phospho-specific-FAK, PARP, p65-NF-KB, phospho-specific p65-NF-KB, and activated-Caspase-3 were from R&D Systems (Heidelberg, Germany). Antibodies to β-Actin, cytochalasin D (CD), MTT reagent [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], DAPI (4,6-diamidino-2-phenylindole), dithiothreitol (DTT) and alginate were from Sigma-Aldrich (Taufkirchen, Germany). Anti-E-cadherin, anti-vimentin, anti-TGF-B1, anti-p-Smad2 and anti-Slug were from Santa Cruz Biotechnology (Santa Cruz, CA, United States). Secondary antibodies for immunofluorescence were procured from Dianova (Hamburg, Germany). Alkaline phosphatase-linked antibodies for Western blotting were obtained from EMD Millipore (Schwalbach, Germany). Calebin A (CA), was a generous gift from Sabinsa Corporation (East Windsor, NJ, United States). Calebin A was diluted and 10,000 µM stock solution was prepared in DMSO, and this was further diluted in cell culture medium. Final concentration of DMSO did not exceed 0.1% during the experiments. Focal adhesion kinase inhibitor (FAK-I) (PF-562271) was purchased from Sellekchem (Munich, Germany). Stock sample of 10 mM FAK-I was prepared in DMSO and diluted again in serum-starved medium to make working samples.

Cell Lines and Cell Culture Conditions

Two distinct colorectal cancer cell lines (HCT116 and RKO), and a stromal fibroblast cell line (MRC-5) were purchased from the European Collection of Cell Cultures (Salisbury, United Kingdom) and a human T-lymphocyte cell line (Jurkat) was obtained from the Leibniz Institute (DSMZ- German Collection of Microorganisms and Cell Cultures). Jurkat was cultured in suspension and HCT116, RKO, and MRC-5 were cultured as monolayers in normal cell growth medium containing 10% FCS under standard conditions (37°C, 5% CO₂) (Shakibaei et al., 2015).

Study Design

TME cultures were set up by co-culturing stromal cells (MRC-5), T-lymphocyte cell line (Jurkat) and CRC cells (HCT116, RKO) to investigate the potential of Calebin A on the suppression of epithelial-to-mesenchymal transition in CRC cells as described previously (Buhrmann et al., 2020a). To establish the multicellular TME, CRC cells (HCT116, RKO) in 3dimensional (3D) alginate cultures (1×10^6 /ml alginate) were transferred to petri dishes containing monolayer fibroblasts ($3,000/\text{cm}^2$) and in suspension T-lymphocytes (20.000/ml medium). These cells were cultured in serum-starved medium (3% FCS) for 10 days. The CRC cells cultured in alginate beads alone were termed as "basal control". All experiments were performed with serum starved medium containing only 3% FCS.

Alginate Culture

As described in detail in our previous studies (Shakibaei and De Souza, 1997; Shakibaei et al., 2015), CRC cells (1x10⁶/ml) were suspended in alginate and dropwise (size: 0.5 cm) added into a sterile CaCl₂ solution (100 mM) where the drops polymerized into beads after 10 min. After continued washing with NaCl (15 mM), alginate beads were incubated for 1 h in serum starved medium. For the experiments, cells were left untreated or treated with CD in a dose dependent manner (0.1, 1, 2, and $4 \mu g/ml$) for 30 min and then encapsulated in alginate beads, and TME cultures were established as described above. Further, primarily untreated TME cultures were treated with Calebin A (1, 2, 5, and 10 µM) or with FAK-I (0.01, 0.1, 1, and 10 µM). As basal control, CRC were encapsulated in alginate beads without fibroblasts or Jurkat and either left untreated or treated with 5 μ M Calebin A. Medium was changed three times a week and cultures were investigated after 10 days.

Viability Assay

Impact of Calebin A on the proliferation of CRC cells in TME cultures was examined by the MTT reagent, as described before (Buhrmann et al., 2020a). Shortly, CRC cells treated as described above were detached from alginate using a sterile sodium citrate solution (55 mM), were re-suspended in altered medium (no phenol red, no vitamin C, 3% FCS) and 10 μ l MTT solvent (5 mg/ ml) was spread per well in a 96-well plate in triplicate. Incubation was stopped after 2 h by adding 10% Triton x-100/acidic isopropanol and metabolically active cells were estimated using a multiscanner plate ELISA reader (Bio-Rad Laboratories Inc. Munich, Germany).

Invasion Test

The cell invasion assay was examined using alginate beads (Shakibaei et al., 2015; Buhrmann et al., 2020a). Shortly, 1 $x10^{6}$ /ml cells were embedded in alginate and treated as described above. After incubation for 10 days, the noninvasive

cells and alginate matrix were removed from the petri dishes while the invasive cells that migrated across the alginate beads adhered and made colonies in opposite to fibroblasts cells on the bottom of the petri dish. These invasive cells were stained with toluidine blue for 1 h and accurate washed two times with PBS and photographed under the light microscope (Zeiss, Germany). The amount of migrating and positively stained attached colonies was quantified and analyzed by counting all colonies.

Immunofluorescence

Immunofluorescence labeling of Slug was performed in a modified TME as described (Buhrmann et al., 2020a). Shortly, HCT116, and RKO cells were seeded on glass plates (5,000/plate) and after adherence, they were either left untreated or treated with CD (1, 2 µg/ml) for 30 min and then placed on a steel-net bridge in petri dishes containing monolayer of fibroblasts (10.000/cm²) and T-lymphocytes in suspension (20.000/ml) to establish TME. Additionally, cultures were either left untreated or treated with Calebin A (1, 5 µM) for 24 h. For basal control, CRC cells were cultured only on glass plates without creating the TME and either left untreated or were treated with Calebin A (5 µM).

Western Blot Analysis

Samples from the TME were processed in the same manner as earlier detailed (Shakibaei et al., 2015; Buhrmann et al., 2017). Shortly, alginate samples were suspended in sterile sodium citrate solution for 20 min, lyzed on ice (50 mM Tris/HCl, pH 7.2/ 150 mM NaCl/(v/v) Triton X-100/1 mM sodium orthovanadate/ 50 mM sodium pyrophosphate/100 mM sodium fluoride/4 µg/ml pepstatin A/1 mM PMSF), total protein content was measured, and fractionated by SDS-PAGE under reducing conditions. After blotting on a nitrocellulose membrane (Transblot apparatus, Bio-Rad, Munich, Germany), membranes were incubated overnight with primary antibody (1:10,000) at 4°C and incubated for 1.5 h with secondary antibody (1:10,000). Positive binding was determined using nitroblue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate (VWR, Germany), quantification of bands was performed using the "Quantity One" program (Bio-Rad, Munich, Germany).

DNA-Binding Assay

To address the role of Calebin A in modulating NF- κ B attachment on DNA, we performed a DNA-binding assay with dithiothreitol (DTT) as earlier detailed (Buhrmann et al., 2020a). TME cultures were established and then nuclei and cytoplasm were separated from each other, from CRC cells that remained untreated and/or treated with Calebin A (1, 2, and 5 μ M) plus DTT (5 mM) alone or in both for 1 h, as has been thoroughly outlined in previous work (Buhrmann et al., 2020a; Buhrmann et al., 2020b; Buhrmann et al., 2020c). The nuclei were then prepared, separated by SDS-PAGE and blotted as indicated earlier. PARP was used to normalize the samples to the controls.

Immunoprecipitation Assay

The immunoprecipitation assay was performed as outlined (Shakibaei et al., 2012) to explore the endogenous interaction of NF- κ B and Slug on CRC grown in TME cultures. Whole cell

extracts of HCT116 and RKO from TME cultures were incubated with 25 μl of either normal rabbit IgG-serum or normal mouse IgG-serum and Staphylococcus aureus cells as pre-clearing. Further, samples were incubated with primary antibodies (anti-p-NF-KB-p65 or anti-Slug) diluted in washing buffer [0.1% Tween 20, 150 mM NaCl, 50 mM Tris-HCl (pH 7.2), 1 mM CaCl₂, 1 mM MgCl₂ and 1 mM PMSF] for 1.5 h (4°C), with S. aureus cells for 1 h and washed three times with washing buffer and once with 50 mM Tris-HCl (pH 7.2). Finally, samples were boiled in SDS-PAGE sample buffer and immunoblotting (anti-p-NF-kB-p65 or anti-Slug) was performed as described above. Additionally, samples were incubated with non-IgG rabbit anti-mouse alone as immune control immunoprecipitations.

Statistics

Each individual assay was tested separately three times using three separate sets of replicates. A Wilcoxon-Mann-Whitney test was used for statistical analysis. Results were presented as mean \pm SD or SEM and compared by one-way, two-way or three-way ANOVA using SPSS Statistics if the normality test was satisfied (Kolmogorov-Smirnov test). A *p*-value of <0.05 was regarded as evidence of statistically important results.

RESULTS

The objective of this presentation was to investigate the subregulatory actions of Calebin A (a component of *C. longa*) (**Figure 1A**) on CRC cells in a pro-inflammatory multicellular TME model to represent an *in vivo* approach TME. In this work, we show for the first time that Calebin A suppresses TMEinduced CRC cell invasion and malignancy by modulating EMT signaling during the early onset of CRC.

Calebin A Blocks TME-Induced Viability and Proliferation of CRC Cells, Comparable to FAK Inhibitor or Cytochalasin D

Given that the organization and rearrangement of the cytoskeleton is essential for the cancer cell invasion, migration, and proliferation (Tai et al., 2015), we first investigated whether Calebin A modifies colorectal cancer cell proliferation and viability in TME, similar to FAK inhibitor or cytochalasin D. Serum-starved HCT116 or RKO cells were kept untreated or treated with different concentrations of Calebin A or FAK inhibitor or CD. Cell viability and proliferation were determined using MTT assay as outlined in Materials and Methods. TME significantly increased cell viability and proliferation of HCT116 and RKO cells compared with basal control (Figures 1B,C). In contrast, Calebin A, similar to FAK inhibitor, or CD reduced markedly TME-promoted cell viability and proliferation of cells in 3Dalginate tumor cultures in both basal control and TME in a dose-dependent way. Collectively, the anti-proliferative action of Calebin A resembles FAK inhibitor or cytochalasin D and these proteins may play a role in its efficacy.



FIGURE 1 Calebin A or FAK inhibitor or cytochalasin D action on colorectal cancer cell survival. (A) Chemical bodies of Calebin A. (B) HCT116 and (C) RKO cells in alginate beads by themselves (basal control = B. Co.) or in TME were firstly not treated, and secondly, were exposed to a series of doses of Calebin A (CA) (1, 2, 5, 10 μ M) or cytochalasin D (CD) (0.1, 1, 2, and 4 μ g/ml) or FAK inhibitor (FAK-I) (0.01, 0.1, 1, and 10 μ M) for 10 days and cell survival was monitored by MTT. All tests were checked on three different occasions each. *p < 0.05, **p < 0.01 relative to basal control.





Calebin A Blocks TME-Induced 3D-Alginate CRC Cell Migration and Invasion, Comparable to Cytochalasin D

To assess the action of Calebin A or CD on the motility and invasion ability of CRC cells through the TME, HCT116, and RKO cells were grown in a 3D-alginate-matrix TME that more closely represents in vivo conditions and handled as outlined in detail in Materials and Methods. As shown in Figures 2A,B, the untreated TME significantly promoted tumor cell migration in CRC cell through the 3D-alginate-based matrix compared with the basal untreated TME control. In contrast, treatment of CRC cells with Calebin A (1, 2, and 5 μ M), similar to CD (0,1, 1, and 2 μ g/ml), blocked CRC cell migration and invasion across the alginate matrix in TME cultures in a dose-dependent way. Taken together, this is consistent with the results of the MTT assay, which showed that Calebin A, similar to CD inhibited CRC cell viability and proliferation, and these data highlight the importance of the involvement of cytoskeletal signaling proteins in the antimetastasis properties supported by Calebin A in TME.

Calebin A Down-Regulated EMT-Related Transcription Factor (Slug) in CRC Cells Comparable to Cytochalasin D, as Shown by Immunofluorescence Microscopy

Slug is a component of the Snail generation of zinc-finger transcription factors (Blanco et al., 2002), and it has been

proposed that Slug is participating in the modulation of cell motility during tumor cell invasion and migration (Cobaleda et al., 2007). To explore the impact of Calebin A on Slug expression in CRC cells, HCT116 and RKO cultures were left untreated or treated with different concentrations of Calebin A or CD and immunolabeled with anti-Slug as described above and evaluated by immunofluorescence microscopy and nuclear labeling with DAPI. In the control TME cultures, HCT116 and RKO cells showed significantly stronger labeling for Slug in the nucleus compared with the basal control (Figures 3A-C). Calebin A treatment, similarly to CD, significantly downregulated the expression of Slug in CRC cells and its nuclear localization in TME cultures, indicating the important pro-inflammatory effects of TME on CRC cells that support tumor promotion. Taken together, these results highlight that Slug is one of the major target proteins of Calebin A for its anti-metastatic or anti-EMT mechanisms in CRC cell TME (Figures 3A-C). Apoptosis was in fact verified by analyzing the apoptosis indicating morphological alterations in the nucleus with DAPI nuclear labeling (Figures 3A-C). Nuclear staining showed that untreated control HCT116 (Figures 3A,B) and RKO (Figure 3C) cell cultures had generally normal nuclear dimensions with only a few apoptotic nuclei in the cultured cells. In contrary, a significant increase in apoptotic cells was observed in cells treated with Calebin A or CD in HCT116 or RKO cells with nuclear morphological alterations (pyknosis, fragmented nuclei, chromatin condensation) in a dosedependent fashion (Figures 3A-C). Taken together, these



carried out for the indicated proteins. *p < 0.05, **p < 0.01 relatively to basal control.

outcomes are in agreement with MTT findings and indicate Calebin A has the ability to act to suppress the pro-tumor actions of TME in CRC cells through repression of EMT as well as induction of apoptosis.

Calebin A Suppressed TME-Induced p-NF-κB-p65, FAK, and Activated TME-Inhibited Caspase-3, Comparable to Cytochalasin D, in CRC Cells

In the past, TMEs have been shown to promote NF- κ B activation and phosphorylation, which has been linked to tumor cell migration and metastasis (Ghosh et al., 1998; Lind et al., 2001; Cho et al., 2007; Sutnar et al., 2007). Therefore, we investigated the expression and phosphorylation of NF- κ B in relation to malignancy and metastasis of CRC cells. Starved HCT116 and RKO cells were grown in alginate matrix beads and co-cultured in TME conditions, followed by treatment with incremental concentrations of Calebin A (1, 2, and 5 μ M), CD (0.1, 1, and 2 μ g/ml) or in culture medium as a control for 10 days as detailed in the Materials and Methods. Samples were immunolabeled using antibodies to p65, phospho-specific p65-NF- κ B, p-FAK, and Caspase-3.

The levels of p65-NF- κ B and p-FAK phosphorylation of HCT116 and RKO-alginate cultures were found to be notably increased in TME compared with basal control cultures. Interestingly, in a manner consistent with the disruption of the cytoskeleton by CD, treatment of TME with Calebin A markedly down-regulated the phosphorylation of p-NF- κ B-p65

and p-FAK in a concentration-dependent way in both cells (**Figure 4**). Calebin A based treatment of TME, similar to CD disruption of the cytoskeleton, significantly upregulated cleaved Caspase-3 protein expression in CRC cells in a dose-dependent way (**Figure 4**). Contrary, treatment with CD resulted in less cleaved Caspase-3 protein compared with Calebin A, and cleavage of Caspase-3 was greater in RKO than in HCT116 CRC cells (**Figure 4**). These results suggest that Calebin A suppresses TME-mediated migration and invasion in CRC cells *via* inhibition of NF- κ B, p-FAK and stimulation of caspase-3.

Calebin A Modulated TME-Induced TGF- β 1 Signaling, Comparable to Cytochalasin D in CRC Cells

The cytokine transforming growth factor- $\beta 1$ (TGF- $\beta 1$) is a crucial factor in tumor progression and a strong enhancer of EMT during tumor invasion and metastasis (Massagué, 2000; Siegel and Massagué, 2003; Derynck and Akhurst, 2007), therefore, next, to determine whether TGF- $\beta 1$ is implicated in augmenting tumor cell proliferation, migration, and the factors that stimulate cancer, we studied TGF- $\beta 1$ protein expression in HCT116 and RKO cells. Starved cells grown in the TME cultures were either kept untreated or treated as mentioned in the "Materials and Methods" paragraph. Both CRC cells exhibited low expression of TGF- $\beta 1$ and p-Smad-2 proteins in basal control (**Figure 5**). Whereas, immunoblotting showed substantially increased levels of TGF- $\beta 1$ and p-Smad-2



FIGURE 5 Calebin A or cytochalasin D actions on TGF- β 1 and p-Smad-2 expression in colorectal cancer cells. (A) HCT116 and (B) RKO cells in alginate beads (B. Co.) or in TME were maintained untreated or treated as outlined to the previous. Immunoblotting of total samples was performed by Western blotting using antibodies to TGF- β 1 and p-Smad-2. Indicated are the results of at least three separate assays, with β -Actin serving as loading control. Densitometric analysis was performed for the indicated proteins. *p < 0.05, **p < 0.01 relatively to basal control.



indicated proteins. *p < 0.05, **p < 0.01 relatively to basal control.

expression in both HCT116 and RKO cells obtained by TME (**Figure 5**). Importantly, in a manner resembling CD-treated cultures, Calebin A was found to considerably down-regulate the expression of the biomarkers mentioned above in a concentration-dependent way (**Figure 5**). Taken together, these outcomes are consonant with those of several other studies documenting that TGF- β 1 and cytokines are the major contributors to progression, invasion, and metastasis within the TME (Derynck and Akhurst, 2007; Li et al., 2014; Jang et al., 2015). Collectively, Calebin A acts against the TMEs and has a potent suppressive effect on the mentioned processes.

Calebin A Modulated TME-Induced Altering the Expression of EMT-Specific Biomarkers, Comparable to Cytochalasin D in CRC Cells

To learn more about the multifunctional role of the Calebin A, in TME-induced tumor malignancy and metastasis in CRC cells, in relation to motility and EMT, we examined the level of EMT-related pathway protein expression, including E-cadherin, vimentin, and Slug. EMT has been reported to have a major function in carcinogenesis by leading to



weakening of cell-cell adhesion, alteration of ECM, and increased motility of cancer cells (Martin, 2014). We investigated the expression of EMT biomarkers for tumorigenicity and the possible effects of Calebin A on these biomarkers. Alginate basal control HCT116 and RKO cells revealed a basal level expression of the aforementioned EMT markers (Figure 6). In contrast, Western blot results showed markedly down-regulated expression of E-cadherin and markedly up-regulated expression of vimentin and Slug in both cells from TME cultures (Figure 6). However, similar to CD, treatment with Calebin A resulted in up-regulation of E-cadherin expression and, in contrast, significant down-regulation of vimentin and Slug expression in a concentrationdependent way, indicating the prominent targeting impact of Calebin A on the EMT signaling pathway (Figure The densitometric analysis 6). of the immunoblots supported the presented findings (Figure 6). Taken together, such data clearly demonstrate the critical function of Calebin A in regulating TMEstimulated EMT pathway, as well as Calebin A mediates anti-metastasis effects in part by down-regulating the EMT pathway of CRC cells in the TME.

DTT Blocks Calebin A-Suppressive Effects of NF-κB Binding to DNA in CRC Cells

We further wanted to know whether Calebin A has the ability to trigger the repression of NF- κ B phosphorylation by directly interfering with its binding to DNA. To address this question, we treated isolated nuclei obtained from HCT116 (A) and RKO (B) cells as indicated in Materials and Methods. To this end, Calebin A markedly attenuated the association of NF- κ B binding to DNA in a dose-dependent way, as demonstrated in **Figures 7A,B**. Since the position 38 cysteine region in p65 protein is required for DNA binding, an assay to remove the cysteine regions was performed with DTT either with or without Calebin A. Indeed, our study revealed that the blocking effect of Calebin A toward the attachment of p65-NF- κ B on DNA has been abolished when DTT was applied to the nuclei of RKO cells, similar to HCT116 cells, indicating a specific effect of Calebin A in regulating the interaction of NF- κ B with DNA and this is not cell specific (**Figures 7A,B**). Taken together, these data suggest that Calebin A directly modulates the binding of p65-NF- κ B to DNA.

Calebin A Inhibits TME-Induced p-NF-κB-p65 Association With the Master EMT-Related Transcription Factor (Slug), Comparable to Cytochalasin D in CRC Cells

Cell motility, cytoskeletal remodeling, cell adhesion, FAK signaling pathways, and NF-KB have already been shown to be linked to the regulation of cancer cell growth, viability, and invasiveness (Cary and Guan, 1999; Schlaepfer et al., 1999; Cheng et al., 2001; Aggarwal, 2004; Zhang et al., 2009). The functional link between the proteins that have a metastasispromoting effect in the TME and their contribution to cancer metastasis is known. We next performed coimmunoprecipitation experiment to provide evidence for a potentially interaction of NF-kB and Slug in CRC cells in TME. Cells were treated as described in Materials and Methods, and cell lysates immunoprecipitated using antibodies directed to p-NF-KB or to Slug, that was subsequently immunoblotted using Slug or p-NF-KB antibodies. As shown in Figure 8, surprisingly, in both CRC found cells. we markedly strong c0immunoprecipitation of NF-kB protein with Slug protein in TME (Figure 8). Marginal co-immunoprecipitation of NF-kB protein with the Slug protein was observed in untreated basal control cultures (Figure 8). However, similar to CD, treatment with Calebin A significantly inhibited this co-immunoprecipitation of NF-KB protein with Slug protein. Densitometric analysis of immunoblots supported the results presented at the top (Figure 8). Overall, our data strongly indicate that, on the one hand TME promotes the formation of the NF-kB/Slug complex during tumorigenesis, resulting in malignancy and metastasis in CRC cells, and, on the other hand Calebin A prevents TME-induced EMT, partly due to blockage of the NF-KB/ Slug route.



DISCUSSION

The present work has allowed us to establish a CRC cell 3Dalginate pro-inflammatory multicellular TME culture mimicking the heterogeneous TME in vivo to evaluate the anti-tumor actions observed with Calebin A, mainly the anti-EMT effect. We provided the following insights and investigated the role of TME in promoting CRC tumor progression (tumor migration and EMT) and the modulatory actions of Calebin A in this process. 1) The TME induced viability, proliferation, and alterations in the expression of biomarkers related to EMT (elevated vimentin, depressed E-cadherin), leading to higher motility and invasiveness in CRC cells. 2) However, these effects were dramatically decreased by Calebin A, similar to FAK inhibitor or CD. 3) In addition, TME induced stabilization of master EMT-related transcription factor (Slug), activation of NF-KB, increased TGF-B1- and p-Smad-2expression, and FAK signaling pathways. 4) Calebin A treatment, similar to CD, significantly reduced TME-induced NF-KB, FAK and Slug signaling and cell migration in both CRC cell lines as well. 5) Calebin A selectively down-regulated the binding of p65-NF-kB on DNA in the two CRC cells, thereby modulating NF-KB-dependent TME-induced EMT signaling. 6) Finally, TME induced a functional connection between NF-KB and Slug, which could enhance Slug-dependent up-regulation of EMT, whereas Calebin A, similar to CD strongly blocked this association of the two transcription factors, thereby blocking EMT.

It has been repeatedly shown in the recent past that threedimensional tumor cultures have excellent culture conditions compared to two-dimensional tumor cultures, as these cultures have a set of suitable *in vivo* conditions for tumor cell survival (Luca et al., 2013; Shakibaei et al., 2015; Stankevicius et al., 2017). The alginate-based substrate provides the appropriate 3D microenvironment for tumor cells to proliferate, form typical tumor spheroids and, very importantly, provides conditions for tumor cells to migrate through the alginate substrate and eventually metastasize. Interestingly, the alginate bead culture is solubilized readily and the living CRC tumor cells can be tested as to their multiple properties in the early steps of proliferation and metastasis further supporting the TME in a manner comparable to *in vivo* (Shakibaei et al., 2015; Buhrmann et al., 2016).

Increasing evidences indicate that there is a direct strong link between inflammation, inflammatory mediators and tumorigenesis. However, the mechanisms by which TME and inflammation enable tumor progression remain poorly understood. It is now recognized that inflammation-induced migration, EMT and metastasis of tumor cells in the TME is a major target of many clinical challenges in tumor treatment (Cordon-Cardo and Prives, 1999; Coussens and Werb, 2002; López-Novoa and Nieto, 2009). In this report, we have shown in invasion assays that the TME induced invasion of cells and this was significantly down-regulated through Calebin A, similar to CD or FAK-inhibitor. This similar mode of action of Calebin A and CD is due to an important target in the cell, namely cytoskeletal proteins, which are critical and essential for cancer cell proliferation, migration and invasion and thus EMT (Tai et al., 2015). This target of Calebin A was further confirmed by the fact that Calebin A also simultaneously inhibits the enzyme responsible for polymerization of cytoskeletal proteins, FAK. In addition, focal contacts are membrane-bound complex structures that create connection among the cytoskeleton and the ECM. FAK plays an essential role as an integrator of biochemical signals and mechanical stimuli and also dominates in active and motile cells. Furthermore, FAK found to have an integral function in controlling DNA synthesis and cytoskeletal organization, thereby regulating cell division, proliferation, and migration (Zhao et al., 1998; Oktay et al., 1999). However, it has been shown that high expression of FAK and FAK signal transduction pathways in various tumor cells and tumor stem cells results in anti-apoptotic effects and tumor cell survival. Indeed, FAK plays a fundamental role in modulating tumor aggressiveness and metastasis, and high FAK expression is always associated with a negative prognosis of tumors (Hungerford et al., 1996; Almeida et al., 2000; Sonoda et al., 2000; Kong et al., 2015; Tai et al., 2015).

We also demonstrated that the transcription factor NF-KB is one of the important stimulated inflammatory down-stream signaling pathways for TME. Similar to the CD pathway, Calebin A has a specific modulatory effect against TMEpromoted activation of NF-KB pathway as well as NF-KBregulated proteins in CRC cells. This finding and our previous studies are consistent with previous research demonstrating that NF-KB becomes activated in tumor cells in responding to diverse groups of pro-inflammatory substances, including cytokines and TME, and inhibits apoptosis (Baeuerle and Baichwal, 1997; Buhrmann et al., 2019; Buhrmann et al., 2020a). After its translocation into the nucleus, it associates with the targeted sequence in DNA, leading in turn to gene transcription. It has already been reported that NF-kB is a promising target for the development of anti-tumor drugs (Van Antwerp et al., 1996; Wang et al., 1996). Indeed, TME-induced NF-kB, is known to be among the major mediators of cancer progression, and thus proliferation and EMT. Thus, NF-KB is associated with tumor metastasis (Pikarsky et al., 2004; Wu and Zhou, 2010). Therefore, compounds like Calebin A, which can block the phosphorylation of NF-kB, have the ability to block tumor promotion and metastasis.

Our data further showed that cytokine transforming growth factor- β 1 (TGF- β 1) and simultaneously, p-Smad-2 expression was significantly up-regulated in TME in both CRC cells. Indeed, it has been previously reported that TME-induced TGF- β 1 expression in CRC cells in a Smad2-dependent process (Jang et al., 2015), and it is known to play a major role in TGF- β 1-induced tumor progression, migration, and EMT (Li et al., 2014). TGF- β 1 induces the signaling pathway for EMT *via* a heteromeric

complex of two transmembrane serine/threonine kinase receptors type I and type-II. This leads to phosphorylation of Smad2 and 3 and 4, whereupon these trimers are transported to the nucleus, where they associate with transcription factors such as Snail and Slug to repress the expression of epithelial markers and induce the expression of mesenchymal markers at the mRNA level (Zhang et al., 2018). Moreover, TGF- β 1 has been shown to promote tumor cell progression and metastasis mainly through EMT and EMT-linked proteins during tumor invasion and metastasis (Buhrmann et al., 2016; Kaowinn et al., 2017).

Interestingly, the concomitant expression of epithelial cell marker (E-cadherin) was markedly decreased and the expression of mesenchymal biomarkers (vimentin and Slug) was markedly increased in the TME. Indeed, down-regulated E-cadherin expression is known to be a specific feature of the EMT process in tumorigenesis (Bendris et al., 2012). Our results clearly show that Calebin A reversed TME-induced changes in the expression of TGF-\$1, p-Smad-2, and EMT biomarkers, similar to CD, in a concentration-dependent manner, suggesting that TME-stimulated EMT can be attenuated in CRC cells. Furthermore, available evidence has recently clearly demonstrated that both genetic and epigenetic influences and factors play important roles in silencing E-cadherin expression in various tumor types (Christofori and Semb, 1999; Cheng et al., 2001). Indeed, it has been further reported that there are some inhibitors of E-cadherin such as the Snail family of zinc finger transcription factors. These transcription factors, as well as Slug, have now been shown to be important modulators of EMT and many other important processes via the influence on E-cadherin in various tumors (Batlle et al., 2000; Cano et al., 2000; Grooteclaes and Frisch, 2000; Comijn et al., 2001; Perez-Moreno et al., 2001; Blanco et al., 2002). It was further reported and clearly demonstrated that Slug, a major EMTrelated transcription factor, has a specific repressive effect on the mouse E-cadherin promoter. Besides, overexpression of Slug in MDCK cells and breast cancer cell lines have been reported to significantly repress endogenous E-cadherin expression, thereby significantly inhibiting cell EMT (invasion and migration) (Hajra et al., 2002; Bolós et al., 2003).

Moreover, our data show that the TME clearly induces the expression of EMT-related transcription factors such as Slug and NF- κ B, indicating targeted EMT activation, and they are known to be highly expressed especially in tumor stem cells and invaded tumor cells (Bhat-Nakshatri et al., 2010; Jang et al., 2015), and Calebin A suppressed the TME-induced expression of Slug and NF- κ B. Indeed, a large body of literature indicates that TME-induced cytokines and pro-inflammatory signaling may promote tumor cell metastasis and EMT signaling (Virchow, 1881; Coussens and Werb, 2002; de Visser et al., 2006; Medzhitov, 2008; Balkwill, 2009; Buhrmann et al., 2020a).

We demonstrated further that TME strongly augmented CRC cell migration and invasion by triggering the EMT signaling pathway *via* NF- κ B-mediated Slug axis stabilization and activation, which plays a critical role in CRC cell metastasis. These results suggest that a synergistic functional interaction of Slug and NF- κ B is required for initiation of EMT and migration of tumor cells. However, when the 3D-alginate CRC tumor cells



were treated with Calebin A, similar to CD, NF- κ B/Slug-axisactivation was markedly inhibited, EMT-related protein expression was significantly reversed, and TME-stimulated active migration and invasion were dramatically reduced.

CONCLUSION

In conclusion, our results report the first evidence that Calebin A can attenuate the TME-promoted EMT, invasion in CRC cells in 3D-alginate beads, similar to CD or FAK-inhibitor *via* regulation of FAK, EMT biomarkers, and TGF- β 1/Smad-2 expression. The inhibitory effect of Calebin A on TME-induced EMT is also associated with suppression of the NF- κ B/Slug axis pathway.

REFERENCES

- Aggarwal, B. B. (2004). Nuclear Factor-Kb. Cancer Cell 6, 203–208. doi:10.1016/ j.ccr.2004.09.003
- Aggarwal, B. B., Yuan, W., Li, S., and Gupta, S. C. (2013). Curcumin-free Turmeric Exhibits Anti-inflammatory and Anticancer Activities: Identification of Novel Components of Turmeric. *Mol. Nutr. Food Res.* 57, 1529–1542. doi:10.1002/ mnfr.201200838
- Almeida, E. A. C., Ilić, D., Han, Q., Hauck, C. R., Jin, F., Kawakatsu, H., et al. (2000). Matrix Survival Signaling. J. Cel Biol 149, 741–754. doi:10.1083/jcb.149.3.741
- Baeuerle, P. A., and Baichwal, V. R. (1997). NF-κB as a Frequent Target for Immunosuppressive and Anti-inflammatory Molecules**This Article Was Accepted for Publication on 27 September 1996. Adv. Immunol. 65, 111–137. doi:10.1016/s0065-2776(08)60742-7
- Balkwill, F. (2009). Tumour Necrosis Factor and Cancer. Nat. Rev. Cancer 9, 361–371. doi:10.1038/nrc2628
- Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., et al. (2000). The Transcription Factor Snail Is a Repressor of E-Cadherin Gene Expression in Epithelial Tumour Cells. *Nat. Cel Biol* 2, 84–89. doi:10.1038/ 35000034
- Behrens, J., Frixen, U., Schipper, J., Weidner, M., and Birchmeier, W. (1992). Cell Adhesion in Invasion and Metastasis. Semin. Cell Biol. 3, 169–178. doi:10.1016/ s1043-4682(10)80013-3

Thus, as a multitargeted component, Calebin A is a promising therapeutic phytopharmaceutical for the treatment of CRC (Figure 9).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

AUTHOR CONTRIBUTIONS

Conceptualization, CB, AB, AK, and MS; methodology, formal analysis and investigation, CB, AB, BA, PK, and MS; writing—original draft preparation, CB, AB, and MS; writing—review and editing, CH, PK, CB, AB, BA, and MS, supervision, MS; project administration, MS. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

We thank Sabine Miech, Anna-Lena Mueller and Andreas Eimannsberger for excellent technical assistance. We also thank Sabinsa Corporation (East Windsor, NJ, United States) for providing Calebin A as a generous gift.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.699842/full#supplementary-material

- Bendris, N., Arsic, N., Lemmers, B., and Blanchard, J. M. (2012). Cyclin A2, Rho GTPases and EMT. *Small GTPases* 3, 225–228. doi:10.4161/sgtp.20791
- Bhat-Nakshatri, P., Appaiah, H., Ballas, C., Pick-Franke, P., Goulet, R., Jr., Badve, S., et al. (2010). SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells with CD44+/CD24- Phenotype. BMC Cancer 10, 411. doi:10.1186/1471-2407-10-411
- Blanco, M. J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J., et al. (2002). Correlation of Snail Expression with Histological Grade and Lymph Node Status in Breast Carcinomas. *Oncogene* 21, 3241–3246. doi:10.1038/sj.onc.1205416
- Bolós, V., Peinado, H., Pérez-Moreno, M. A., Fraga, M. F., Esteller, M., and Cano, A. (2003). The Transcription Factor Slug Represses E-Cadherin Expression and Induces Epithelial to Mesenchymal Transitions: a Comparison with Snail and E47 Repressors. J. Cel Sci 116, 499–511.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer J. Clin.* 68, 394–424. doi:10.3322/caac.21492
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2020). Erratum: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 70, 313. doi:10.3322/caac.21609
- Buccafusca, G., Proserpio, I., Tralongo, A. C., Rametta Giuliano, S., and Tralongo, P. (2019). Early Colorectal Cancer: Diagnosis, Treatment and Survivorship Care. *Crit. Rev. Oncology/Hematology* 136, 20–30. doi:10.1016/j.critrevonc.2019.01.023

- Buhrmann, C., Kunnumakkara, A. B., Popper, B., Majeed, M., Aggarwal, B. B., and Shakibaei, M. (2020a). Calebin A Potentiates the Effect of 5-FU and TNF- β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-Kb. *Int. J. Mol. Sci.* 21. doi:10.3390/ijms21072393
- Buhrmann, C., Popper, B., Kunnumakkara, A. B., Aggarwal, B. B., and Shakibaei, M. (2019). Evidence that Calebin A, a Component of Curcuma Longa Suppresses NF-B Mediated Proliferation, Invasion and Metastasis of Human Colorectal Cancer Induced by TNF-β (Lymphotoxin). *Nutrients* 11, 2904. doi:10.3390/nu11122904
- Buhrmann, C., Shayan, P., Banik, K., Kunnumakkara, A. B., Kubatka, P., Koklesova, L., et al. (2020b). Targeting NF-Kb Signaling by Calebin A, a Compound of Turmeric, in Multicellular Tumor Microenvironment: Potential Role of Apoptosis Induction in CRC Cells. *Biomedicines* 8, 236. doi:10.3390/biomedicines8080236
- Buhrmann, C., Shayan, P., Brockmueller, A., and Shakibaei, M. (2020c). Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study. Molecules 25, 4292. doi:10.3390/molecules25184292
- Buhrmann, C., Shayan, P., Goel, A., and Shakibaei, M. (2017). Resveratrol Regulates Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. *Nutrients* 9, 1073. doi:10.3390/nu9101073
- Buhrmann, C., Shayan, P., Popper, B., Goel, A., and Shakibaei, M. (2016). Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. *Nutrients* 8, 145. doi:10.3390/nu8030145
- Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., Del Barrio, M. G., et al. (2000). The Transcription Factor Snail Controls Epithelial-Mesenchymal Transitions by Repressing E-Cadherin Expression. *Nat. Cell Biol.* 2, 76–83. doi:10.1038/35000025
- Cary, L. A., and Guan, J. L. (1999). Focal Adhesion Kinase in Integrin-Mediated Signaling. Front. Biosci. 4, D102–D113. doi:10.2741/cary
- Cheng, C.-W., Wu, P.-E., Yu, J.-C., Huang, C.-S., Yue, C.-T., Wu, C.-W., et al. (2001). Mechanisms of Inactivation of E-Cadherin in Breast Carcinoma: Modification of the Two-Hit Hypothesis of Tumor Suppressor Gene. Oncogene 20, 3814–3823. doi:10.1038/sj.onc.1204505
- Cho, Y. B., Lee, W. Y., Song, S. Y., Shin, H. J., Yun, S. H., and Chun, H.-K. (2007). Matrix Metalloproteinase-9 Activity Is Associated with Poor Prognosis in T3-T4 Node-Negative Colorectal Cancer. *Hum. Pathol.* 38, 1603–1610. doi:10.1016/j.humpath.2007.03.018
- Christofori, G., and Semb, H. (1999). The Role of the Cell-Adhesion Molecule E-Cadherin as a Tumour-Suppressor Gene. *Trends Biochem. Sci.* 24, 73–76. doi:10.1016/s0968-0004(98)01343-7
- Cobaleda, C., Pérez-Caro, M., Vicente-Dueñas, C., and Sánchez-García, I. (2007). Function of the Zinc-Finger Transcription FactorSNAI2in Cancer and Development. Annu. Rev. Genet. 41, 41–61. doi:10.1146/ annurev.genet.41.110306.130146
- Comijn, J., Berx, G., Vermassen, P., Verschueren, K., Van Grunsven, L., Bruyneel, E., et al. (2001). The Two-Handed E Box Binding Zinc finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion. *Mol. Cel.* 7, 1267–1278. doi:10.1016/s1097-2765(01)00260-x
- Cordon-Cardo, C., and Prives, C. (1999). At the Crossroads of Inflammation and Tumorigenesis. J. Exp. Med. 190, 1367–1370. doi:10.1084/jem.190.10.1367
- Coussens, L. M., and Werb, Z. (2002). Inflammation and Cancer. Nature 420, 860–867. doi:10.1038/nature01322
- De Visser, K. E., Eichten, A., and Coussens, L. M. (2006). Paradoxical Roles of the Immune System during Cancer Development. Nat. Rev. Cancer 6, 24–37. doi:10.1038/nrc1782
- Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., and Wallace, M. B. (2019). Colorectal Cancer. *The Lancet* 394, 1467–1480. doi:10.1016/s0140-6736(19)32319-0
- Del Barrio, M. G., and Nieto, M. A. (2002). Overexpression of Snail Family Members Highlights Their Ability to Promote Chick Neural Crest Formation. *Development* 129, 1583–1593. doi:10.1242/dev.129.7.1583
- Derynck, R., and Akhurst, R. J. (2007). Differentiation Plasticity Regulated by TGF- β Family Proteins in Development and Disease. *Nat. Cel Biol* 9, 1000–1004. doi:10.1038/ncb434
- Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., and Flavell, R. A. (2013). Inflammation-induced Cancer: Crosstalk between Tumours, Immune Cells and Microorganisms. *Nat. Rev. Cancer* 13, 759–771. doi:10.1038/nrc3611

- Ghosh, S., May, M. J., and Kopp, E. B. (1998). NF-Kb and REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses. Annu. Rev. Immunol. 16, 225–260. doi:10.1146/annurev.immunol.16.1.225
- Grooteclaes, M. L., and Frisch, S. M. (2000). Evidence for a Function of CtBP in Epithelial Gene Regulation and Anoikis. *Oncogene* 19, 3823–3828. doi:10.1038/ sj.onc.1203721
- Guo, S., and Deng, C.-X. (2018). Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation. Int. J. Biol. Sci. 14, 2083–2093. doi:10.7150/ijbs.25720
- Hajra, K. M., Chen, D. Y., and Fearon, E. R. (2002). The SLUG Zinc-finger Protein Represses E-Cadherin in Breast Cancer. *Cancer Res.* 62, 1613–1618.
- Hungerford, J. E., Compton, M. T., Matter, M. L., Hoffstrom, B. G., and Otey, C. A. (1996). Inhibition of pp125FAK in Cultured Fibroblasts Results in Apoptosis. *J. Cell Biol.* 135, 1383–1390. doi:10.1083/jcb.135.5.1383
- Jang, M. H., Kim, H. J., Kim, E. J., Chung, Y. R., and Park, S. Y. (2015). Expression of Epithelial-Mesenchymal Transition-Related Markers in Triple-Negative Breast Cancer: ZEB1 as a Potential Biomarker for Poor Clinical Outcome. *Hum. Pathol.* 46, 1267–1274. doi:10.1016/j.humpath.2015.05.010
- Jing, Y., Han, Z., Zhang, S., Liu, Y., and Wei, L. (2011). Epithelial-Mesenchymal Transition in Tumor Microenvironment. *Cell Biosci.* 1, 29. doi:10.1186/2045-3701-1-29
- Kalluri, R., and Weinberg, R. A. (2009). The Basics of Epithelial-Mesenchymal Transition. J. Clin. Invest. 119, 1420–1428. doi:10.1172/jci39104
- Kaowinn, S., Kim, J., Lee, J., Shin, D. H., Kang, C.-D., Kim, D.-K., et al. (2017). Cancer Upregulated Gene 2 Induces Epithelial-Mesenchymal Transition of Human Lung Cancer Cells via TGF-β Signaling. Oncotarget 8, 5092–5110. doi:10.18632/oncotarget.13867
- Kong, D., Chen, F., and Sima, N. (2015). Inhibition of Focal Adhesion Kinase Induces Apoptosis in Bladder Cancer Cells via Src and the Phosphatidylinositol 3-kinase/Akt Pathway. Exp. Ther. Med. 10, 1725–1731. doi:10.3892/ etm.2015.2745
- Labonne, C., and Bronner-Fraser, M. (2000). Snail-related Transcriptional Repressors Are Required in Xenopus for Both the Induction of the Neural Crest and its Subsequent Migration. *Develop. Biol.* 221, 195–205. doi:10.1006/ dbio.2000.9609
- Li, N., Xu, H., Fan, K., Liu, X., Qi, J., Zhao, C., et al. (2014). Altered β1,6-GlcNAc Branched N -glycans Impair TGF-β-mediated Epithelial-to-Mesenchymal Transition through Smad Signalling Pathway in Human Lung Cancer. J. Cell. Mol. Med. 18, 1975–1991. doi:10.1111/jcmm.12331
- Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., et al. (2001). Nuclear Factor-Kb Is Upregulated in Colorectal Cancer. *Surgery* 130, 363–369. doi:10.1067/msy.2001.116672
- López-Novoa, J. M., and Nieto, M. A. (2009). Inflammation and EMT: an alliance towards Organ Fibrosis and Cancer Progression. *EMBO Mol. Med.* 1, 303–314. doi:10.1002/emmm.200900043
- Luca, A. C., Mersch, S., Deenen, R., Schmidt, S., Messner, I., Schäfer, K. L., et al. (2013). Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines. *PLoS One* 8, e59689. doi:10.1371/journal.pone.0059689
- Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 133, 704–715. doi:10.1016/j.cell.2008.03.027
- Martin, T. A. (2014). The Role of Tight Junctions in Cancer Metastasis. Semin. Cell Develop. Biol. 36, 224–231. doi:10.1016/j.semcdb.2014.09.008
- Massagué, J. (2000). How Cells Read TGF-β Signals. Nat. Rev. Mol. Cell Biol. 1, 169–178. doi:10.1038/35043051
- Mauri, G., Sartore-Bianchi, A., Russo, A. G., Marsoni, S., Bardelli, A., and Siena, S. (2019). Early-onset Colorectal Cancer in Young Individuals. *Mol. Oncol.* 13, 109–131. doi:10.1002/1878-0261.12417
- Medzhitov, R. (2008). Origin and Physiological Roles of Inflammation. *Nature* 454, 428–435. doi:10.1038/nature07201
- Nair, A., Amalraj, A., Jacob, J., Kunnumakkara, A. B., and Gopi, S. (2019). Non-Curcuminoids from Turmeric and Their Potential in Cancer Therapy and Anticancer Drug Delivery Formulations. *Biomolecules* 9, 13. doi:10.3390/biom9010013
- Nieto, M. A. (2002). The Snail Superfamily of Zinc-finger Transcription Factors. Nat. Rev. Mol. Cel Biol. 3, 155–166. doi:10.1038/nrm757
- Oktay, M., Wary, K. K., Dans, M., Birge, R. B., and Giancotti, F. G. (1999). Integrinmediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun

NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle. J. Cell Biol. 145, 1461–1470. doi:10.1083/jcb.145.7.1461

- Park, S.-Y., and Kim, D. S. H. L. (2002). Discovery of Natural Products fromCurcumalongathat Protect Cells from Beta-Amyloid Insult: A Drug Discovery Effort against Alzheimer's Disease. J. Nat. Prod. 65, 1227–1231. doi:10.1021/np010039x
- Pérez-Moreno, M. A., Locascio, A., Rodrigo, I., Dhondt, G., Portillo, F., Nieto, M. A., et al. (2001). A New Role for E12/E47 in the Repression ofE-Cadherin Expression and Epithelial-Mesenchymal Transitions. J. Biol. Chem. 276, 27424–27431. doi:10.1074/jbc.m100827200
- Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. (2004). NF-κB Functions as a Tumour Promoter in Inflammation-Associated Cancer. *Nature* 431, 461–466. doi:10.1038/nature02924
- Polyak, K., and Weinberg, R. A. (2009). Transitions between Epithelial and Mesenchymal States: Acquisition of Malignant and Stem Cell Traits. *Nat. Rev. Cancer* 9, 265–273. doi:10.1038/nrc2620
- Prieto-García, E., Díaz-García, C. V., García-Ruiz, I., and Agulló-Ortuño, M. T. (2017). Epithelial-to-mesenchymal Transition in Tumor Progression. *Med. Oncol.* 34, 122. doi:10.1007/s12032-017-0980-8
- Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. (1999). Signaling through Focal Adhesion Kinase. Prog. Biophys. Mol. Biol. 71, 435–478. doi:10.1016/s0079-6107(98)00052-2
- Seguin, L., Desgrosellier, J. S., Weis, S. M., and Cheresh, D. A. (2015). Integrins and Cancer: Regulators of Cancer Stemness, Metastasis, and Drug Resistance. *Trends Cell Biol.* 25, 234–240. doi:10.1016/j.tcb.2014.12.006
- Shakibaei, M., and De Souza, P. (1997). Differentiation of Mesenchymal Limb Bud Cells to Chondrocytes in Alginate Beads. *Cell Biol. Int.* 21, 75–86. doi:10.1006/ cbir.1996.0119
- Shakibaei, M., Kraehe, P., Popper, B., Shayan, P., Goel, A., and Buhrmann, C. (2015). Curcumin Potentiates Antitumor Activity of 5-fluorouracil in a 3D Alginate Tumor Microenvironment of Colorectal Cancer. *BMC Cancer* 15, 250. doi:10.1186/s12885-015-1291-0
- Shakibaei, M., Shayan, P., Busch, F., Aldinger, C., Buhrmann, C., Lueders, C., et al. (2012). Resveratrol Mediated Modulation of Sirt-1/Runx2 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells: Potential Role of Runx2 Deacetylation. *PLoS One* 7, e35712. doi:10.1371/ journal.pone.0035712
- Siegel, P. M., and Massagué, J. (2003). Cytostatic and Apoptotic Actions of TGFβ in Homeostasis and Cancer. Nat. Rev. Cancer 3, 807–820. doi:10.1038/ nrc1208
- Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., et al. (2020). Colorectal Cancer Statistics, 2020. CA A. Cancer J. Clin. 70, 145–164. doi:10.3322/caac.21601
- Sonoda, Y., Matsumoto, Y., Funakoshi, M., Yamamoto, D., Hanks, S. K., and Kasahara, T. (2000). Anti-apoptotic Role of Focal Adhesion Kinase (FAK). J. Biol. Chem. 275, 16309–16315. doi:10.1074/jbc.275.21.16309
- Soria, G., Ofri-Shahak, M., Haas, I., Yaal-Hahoshen, N., Leider-Trejo, L., Leibovich-Rivkin, T., et al. (2011). Inflammatory Mediators in Breast Cancer: Coordinated Expression of TNFα & IL-1β with CCL2 & CCL5 and Effects on Epithelial-To-Mesenchymal Transition. *BMC Cancer* 11, 130. doi:10.1186/1471-2407-11-130
- Stankevicius, V., Kunigenas, L., Stankunas, E., Kuodyte, K., Strainiene, E., Cicenas, J., et al. (2017). The Expression of Cancer Stem Cell Markers in Human Colorectal Carcinoma Cells in a Microenvironment Dependent Manner. *Biochem. Biophys. Res. Commun.* 484, 726–733. doi:10.1016/ j.bbrc.2017.01.111

- Stetler-Stevenson, W. G., Liotta, L. A., and Kleiner, D. E., Jr. (1993). Extracellular Matrix 6: Role of Matrix Metalloproteinases in Tumor Invasion and Metastasis. *Faseb J* 7, 1434–1441. doi:10.1096/fasebj.7.15.8262328
- Sutnar, A., Pesta, M., Liska, V., Treska, V., Skalicky, T., Kormunda, S., et al. (2007). Clinical Relevance of the Expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA Tissue Samples from Colorectal Liver Metastases. *Tumor Biol.* 28, 247–252. doi:10.1159/000110897
- Tai, Y. L., Chen, L. C., and Shen, T. L. (2015). Emerging Roles of Focal Adhesion Kinase in Cancer. *Biomed. Res. Int.* 2015, 690690. doi:10.1155/2015/690690
- Tamura, G., Yin, J., Wang, S., Fleisher, A. S., Zou, T., Abraham, J. M., et al. (2000). E-cadherin Gene Promoter Hypermethylation in Primary Human Gastric Carcinomas. J. Natl. Cancer Inst. 92, 569–573. doi:10.1093/jnci/92.7.569
- Tepass, U., Truong, K., Godt, D., Ikura, M., and Peifer, M. (2000). Cadherins in Embryonic and Neural Morphogenesis. *Nat. Rev. Mol. Cell Biol.* 1, 91–100. doi:10.1038/35040042
- Thiery, J. P. (2002). Epithelial-mesenchymal Transitions in Tumour Progression. *Nat. Rev. Cancer* 2, 442–454. doi:10.1038/nrc822
- Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996). Suppression of TNF-Alpha -Induced Apoptosis by NF-Kappa B. Science 274, 787–789. doi:10.1126/science.274.5288.787
- Virchow, R. (1881). An Address on the Value of Pathological Experiments. Bmj 2, 198–203. doi:10.1136/bmj.2.1075.198
- Wang, C.-Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996). TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-Kappa B. Science 274, 784–787. doi:10.1126/science.274.5288.784
- Wu, Y., and Zhou, B. P. (2010). TNF-α/NF-κB/Snail Pathway in Cancer Cell Migration and Invasion. Br. J. Cancer 102, 639–644. doi:10.1038/sj.bjc.6605530
- Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., and Hirohashi, S. (1995). Silencing of the E-Cadherin Invasion-Suppressor Gene by CpG Methylation in Human Carcinomas. *Proc. Natl. Acad. Sci.* 92, 7416–7419. doi:10.1073/pnas.92.16.7416
- Zeng, Y., Qiu, F., Takahashi, K., Liang, J., Qu, G., and Yao, X. (2007). New Sesquiterpenes and Calebin Derivatives from Curcuma Longa. *Chem. Pharm. Bull.* 55, 940–943. doi:10.1248/cpb.55.940
- Zhang, Q., Helfand, B. T., Jang, T. L., Zhu, L. J., Chen, L., Yang, X. J., et al. (2009). Nuclear Factor-Kb-Mediated Transforming Growth Factor-β-Induced Expression of Vimentin Is an Independent Predictor of Biochemical Recurrence after Radical Prostatectomy. *Clin. Cancer Res.* 15, 3557–3567. doi:10.1158/1078-0432.ccr-08-1656
- Zhang, X., Zhang, P., Shao, M., Zang, X., Zhang, J., Mao, F., et al. (2018). SALL4 Activates TGF-β/SMAD Signaling Pathway to Induce EMT and Promote Gastric Cancer Metastasis. *Cmar* 10, 4459–4470. doi:10.2147/cmar.s177373
- Zhao, J.-H., Reiske, H., and Guan, J.-L. (1998). Regulation of the Cell Cycle by Focal Adhesion Kinase. J. Cell Biol. 143, 1997–2008. doi:10.1083/jcb.143.7.1997

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Buhrmann, Brockmueller, Harsha, Kunnumakkara, Kubatka, Aggarwal and Shakibaei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.